SCHEMBL2127608

SCHEMBL2127608

COc1c(C=Cc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)CO

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.82
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
TRPV1 Q8NER1 2/20 0.33
PADI4 Q9UM07 1/20 0.33
PDPK1 O15530 1/20 0.32
PDCD1 Q15116 5/20 0.32
CD274 Q9NZQ7 5/20 0.32
CRBN Q96SW2 1/20 0.32
BRD4 O60885 1/20 0.31
EP300 Q09472 1/20 0.31
IKBKB O14920 1/20 0.31
CHUK O15111 1/20 0.31
PRKAB2 O43741 1/20 0.31
PRKAG1 P54619 1/20 0.31
PRKAA2 P54646 1/20 0.31
PRKAA1 Q13131 1/20 0.31
PRKAG3 Q9UGI9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127605 1.00 CYP3A4 (0.82) CYP3A4JAK2JAK1TYK2JAK3
SCHEMBL2128077 0.91 CYP3A4 (1.00) CYP3A4JAK2JAK1TYK2JAK3
SCHEMBL2128074 0.91 CYP3A4 (1.00) CYP3A4JAK2JAK1TYK2JAK3
SCHEMBL2127937 0.89 CYP3A4 (0.87) CYP3A4JAK2JAK1TYK2JAK3
SCHEMBL1542867 0.89 CYP3A4 (0.87) CYP3A4JAK2JAK1TYK2JAK3
SCHEMBL3189204 0.88 CYP3A4 (0.85) CYP3A4JAK2JAK1TYK2JAK3
SCHEMBL3189211 0.88 CYP3A4 (0.85) CYP3A4JAK2JAK1TYK2JAK3
SCHEMBL1543113 0.88 CYP3A4 (0.85) CYP3A4TRPV1PADI4PDPK1BRD4
SCHEMBL2128091 0.88 CYP3A4 (0.85) CYP3A4TRPV1PADI4PDPK1BRD4
SCHEMBL1542989 0.88 CYP3A4 (0.81) CYP3A4JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885JAK2 526/4885JAK1 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.